Eurofins Scientific SE

Eurofins Scientific has completed its acquisition of Element Materials Technology's Life Sciences Testing Services business in North America, with the deal closing on 1 October 2026. The transaction was first announced on 20 July 2026 at an enterprise value of USD400m. The acquired business operates a network of 27 laboratories and facilities, employs approximately 750 staff, and is expected to generate annual revenues of over USD150m in 2026, with profitability similar to the Eurofins Group average. The operations will join Eurofins' BioPharma and Life businesses in North America, extending its laboratory network into key regions of the United States and Canada where it has historically been underrepresented. Eurofins CEO Dr Gilles Martin said the company welcomes Element's North American Life Sciences Testing Services teams and will build on its laboratory platform to serve customers across the continent.

Eurofins Scientific SE has completed the divestment of its Electrical & Electronic Testing business, known as MET Labs, to UL Solutions Inc., with the transaction closing on 1 October 2026. The deal was first announced on 14 April 2026 at an Enterprise Value of €575 million on a cash and debt free basis. MET Labs operates an international network of laboratories providing product safety testing, inspection and certification services for electrical and electronics products, employing approximately 1,300 staff globally. Eurofins said the transaction supports its focus on allocating capital toward its core testing for life capabilities, with proceeds earmarked for debt reduction, laboratory and owned-site capital expenditure, next-generation digital solutions, robotics and AI developments, share buybacks and strategic acquisitions in food, environmental, pharmaceutical, clinical and related testing areas. Chief Executive Dr Gilles Martin thanked the MET Labs teams for building successful and in several cases leading businesses over almost 20 years within the Eurofins network, adding that UL Solutions' focus on applied safety science makes it a natural home for the laboratories.

Eurofins Scientific SE bought back 100,000 of its own shares between August 3 and August 7, 2026, at a daily volume of 20,000 shares each day. The daily weighted average purchase prices ranged from 68.4085 euros to 70.3102 euros, with an overall average of 69.3844 euros. All transactions were executed on the XPAR market.

Eurofins Scientific repurchased a total of 85,000 of its own shares between July 20 and July 24, 2026, at a daily weighted average purchase price of 68.3251 euros. The transactions were executed across the XPAR and CEUX markets, with daily volumes ranging from 3,180 to 20,000 shares. The highest daily average price was 70.8332 euros on July 20, while the lowest was 66.1178 euros on July 24. A full breakdown of individual trades is available on the company's website in accordance with the Market Abuse Regulation.

Eurofins Scientific posted a 29% year-on-year increase in earnings per share for the first half of 2026, alongside an adjusted EBITDA margin of 23.7% that exceeded its own objectives. Reported EBITDA margin reached 23.3%, a 190 basis point improvement, while free cash flow surged 46% to EUR 403 million, driving cash conversion to a record 47%. Organic growth came in at 2.7%, held back by a 2.9% foreign-exchange headwind and softness in biopharma, though the rest of the world delivered 9% organic revenue growth. The company also executed EUR 200 million in share buybacks, kept leverage stable at 2.2 times, and saw margin gains of 210 basis points in Europe and 230 basis points in North America excluding one-time items.

The global cell-based assay services for preclinical use only market reached approximately $4.47 billion in 2025 and is projected to grow to $12.93 billion by 2035, according to a new report from ResearchAndMarkets.com. The market recorded a compound annual growth rate of 12.3% from 2020 and is forecast to expand at 11.5% through 2030 before reaching the 2035 figure. Cytotoxicity assays were the largest segment in 2025, accounting for 30.8% of the market, while phenotypic and morphological assays are expected to be the fastest-growing category through 2030. North America led regional revenue with a 40.1% share in 2025, but Asia-Pacific is forecast to be the fastest-growing region with a 15.2% CAGR through 2030. Leading companies profiled include Charles River Laboratories, Labcorp Drug Development, Eurofins Scientific, and Evotec, with the top 10 competitors holding 19.17% of the market in 2024.

Analytical Bioventures S.C.A., a company controlled by Eurofins Scientific CEO Dr. Gilles Martin, acquired a total of 3,000 shares of Eurofins Scientific across three transactions on the Euronext Paris exchange. The purchases were made on June 25 at EUR 67.7737 per share, June 26 at EUR 68.4577 per share, and June 29 at EUR 68.4011 per share, for an aggregated total of EUR 204,632.50. The notifications were made in accordance with the European Market Abuse Regulation.

Eurofins Scientific repurchased a total of 130,000 of its own shares between 22 June and 26 June 2026, at a daily volume-weighted average price of €65.7977. The buybacks were executed across the XPAR and CEUX markets, with daily volumes ranging from 25,000 to 30,000 shares and average daily prices rising from about €62.73 on 22 June to €68.45 on 26 June. A full breakdown of individual trades is available on the company’s website in accordance with the EU Market Abuse Regulation.

Analytical Bioventures S.C.A, a company controlled by Eurofins Scientific S.E. CEO Dr. Gilles Martin, has acquired a total of 6,000 shares of Eurofins Scientific S.E. across three separate transactions. The purchases were made on June 17, 18, and 19, 2026, each for 2,000 shares at prices of EUR 62.27000, EUR 62.1825, and EUR 62.746 respectively, resulting in a total investment of EUR 374,289.00. All transactions took place on the XPAR venue and were disclosed in accordance with the European Market Abuse Regulation.